EUR 107.18 For Business Accounts Only

Synergy Pharmaceuticals Inc - Strategic SWOT Analysis Review

Synergy Pharmaceuticals Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – GlobalData’s summarization of the company’s business strategy.
- SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.

Highlights

Synergy Pharmaceuticals Inc (Synergy Pharma) is a biopharmaceutical company that develops and commercializes new treatments for gastrointestinal (GI) diseases. The company pioneered its R&D efforts to develop its proprietary uroguanylin-based GI platform. It is also developing analogs of uroguanylin, a naturally occurring human GI peptide that promotes normal bowel function. The company’s portfolio includes Trulance (plecanatide), which is structurally identical to uroguanylin, for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) in adults. Synergy Pharma’s pipeline includes dolcanatide (SP-333), an investigational candidate under evaluation for the treatment of OIC and UC. Synergy Pharma is headquartered in New York, the US.

Synergy Pharmaceuticals Inc Key Recent Developments

Mar 01,2019: Synergy Pharmaceuticals receives court approval for the sale of its assets to Bausch Health
Jan 08,2019: Sure Med Compliance partners with Synergy Laboratories to advance the fight against opioid abuse
Dec 14,2018: Bausch Health makes $200m bid for bankrupt Synergy Pharmaceuticals
Nov 08,2018: Synergy Pharmaceuticals reports third quarter 2018 financial results and business update
Oct 31,2018: Synergy Pharmaceuticals names Dr. Melvin K. Spigelman Chairman

Reasons to Buy

- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.